The man took over services at a Texas synagogue where he could be heard ranting on a livestream.
Suspect dead and all hostages safe after FBI storms Texas synagogue
Beam Therapeutics (NASDAQ: BEAM) recently signed a major research deal with Pfizer (NYSE: PFE) that could be worth up to $1.35 billion, and hardly anyone seemed to notice. Instead of surging higher in response to the Pfizer deal, Beam Therapeutics stock actually fell nearly 2% on the day of the announcement. Over the past few years, Pfizer has watched its peers experiment with CRISPR-based gene editing techniques without making any significant investments.